TARGETING EZH2-RB INTERACTIONS TO OVERCOME CANCER THERAPY RESISTANCE

GMU-25-034

## PRECISION ONCOLOGY REDEFINED

Mason's innovative platform identifies and targets newly discovered signaling axis between EZH2 and phosphorylated Rb (pRb) – a key driver of resistance in metastatic cancers. This technology enables both diagnostic testing and targeted treatment to personalize therapy and improve outcomes.

- ☑ **Predicts Therapy Resistance –** Detects EZH2 overexpression and EZH2-pRB interactions to guide treatment decisions.
- ☑ **Restores Tumor Sensitivity –** Uses EZH2 degraders to disrupt non-canonical EZH2 functions and reactive Rb.
- ☑ **Broad Cancer Coverage –** Applicable to breast, lung, prostate, and other epithelial cancers.
- ☑ **Actionable Diagnostics –** Compatible with IHC, RPPA, and PLA for easy clinical adoption.
- ☑ **Commercially Ready –** High-value opportunity for pharma and diagnostics companies seeking next-gen oncology solutions.